NCT00306566已完成1 期
A Phase IIa Study to Evaluate Safety, Tolerability, and Immunogenicity of a Melan-A VLP Vaccine in HLA-A2 Positive Patients With Stage II Malignant Melanoma
适应症
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 试验地点
- 1
研究概览
简要总结
The purpose of this study is to monitor a specific cellular immune response in melanoma patients at an early stage of the disease, that have been vaccinated with a Melan-A VLP vaccine.
研究设计
- 研究类型
- Interventional
- 分配方式
- Non Randomized
- 干预模型
- Single Group
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Able to provide written informed consent
- •Able and willing to complete all protocol requirements
- •Age: 18 years and older
- •Histological confirmed stage II melanoma
- •HLA-A*0201 haplotype
- •Expected survival of at least 6 months
- •ECOG performance status of 0 or 1
- •Full recovery from surgery
- •Adequate organ and bone marrow functions
- •Sexually active males should use adequate contraception throughout the study period and 3 months thereafter.
- •Females of child bearing potential should use adequate contraception throughout the study period and 3 months thereafter, that can be oral contraception or a double-barrier local contraception (intra-uterine device plus condom or spermicidal gel plus condom), and have a negative serum pregnancy test within 4 weeks prior to the first dose of the vaccine.
排除标准
- •Pregnant or nursing
- •Use of an investigational drug within 30 days before enrolment
- •Active malignancy in the 5 years prior to enrollment other than melanoma, basal cell carcinoma or cervical carcinoma in situ.
- •Major surgery within 4 weeks prior to enrollment.
- •Current use of an immunosuppressive drug or any concomitant medication that could potentially interfere with the study drug (e.g. steroids, antihistamine drugs; topical or inhalational steroids are permitted).
- •Presence of significant cardiovascular, renal, pulmonary, endocrine, infectious, or neurological disorders.
- •Serum tests positive for HIV, HBV, HCV.
- •Active autoimmune diseases or severe allergies.
- •Current diagnosis or history of relevant and severe psychiatric disorder that compromises the patient's ability to understand the patient information, to give informed consent, to comply with the trial protocol or to complete the study.
- •Blood donation or loss of > 500mL within 8 weeks prior to inclusion.
- •Abuse of alcohol or other recreational drugs.
- •Previous vaccination with a Melan-A analog peptide.
研究者
研究点 (1)
Loading locations...
相似试验
已完成
1 期
Phase I/II Study of Chemo-Immunotherapy Combination in Melanoma PatientsMelanomaNCT00559026Istituto Superiore di Sanità10
终止
1 期
Local Modulation of Immune Receptors to Enhance the Response to Dendritic Cell Vaccination in Metastatic MelanomaMetastatic MelanomaNCT01216436Duke University2
撤回
2 期
Study of Immune Responses in Patients With Metastatic MelanomaMetastatic MelanomaNCT01416844Providence Health & Services
已完成
2 期
Safety and Immunogenicity of CYT004-MelQbG10 Vaccine With and Without Adjuvant in Advanced Stage Melanoma PatientsMalignant MelanomaNCT00651703Cytos Biotechnology AG21
终止
2 期
Phase II Study to Assess the Safety and Immunogenicity of recMAGE-A3+AS15 ASCI With or Without Poly IC:LCMelanomaNCT01437605H. Lee Moffitt Cancer Center and Research Institute14